Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study.

MLA

Iacovoni, Attilio, et al. “Natriuretic Peptides and the Framingham Risk Score for Screening of Asymptomatic Left Ventricular Systolic Dysfunction in High-Risk Patients in Primary Care. The DAVID-BERG Study.” International Journal of Cardiology, vol. 168, no. 5, Oct. 2013, pp. 5093–95. EBSCOhost, https://doi.org/10.1016/j.ijcard.2013.07.260.

APA

Iacovoni, A., De Maria, R., Gavazzi, A., Grosu, A., Fontana, A., Guideri, S., Gori, M., Ferrari, P., Filippi, A., Rutili, M. R., Donzelli, L., Parolini, M., & Senni, M. (2013). Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study. International Journal of Cardiology, 168(5), 5093–5095. https://doi.org/10.1016/j.ijcard.2013.07.260

Chicago

Iacovoni, Attilio, Renata De Maria, Antonello Gavazzi, Aurelia Grosu, Alessandra Fontana, Silvia Guideri, Mauro Gori, et al. 2013. “Natriuretic Peptides and the Framingham Risk Score for Screening of Asymptomatic Left Ventricular Systolic Dysfunction in High-Risk Patients in Primary Care. The DAVID-BERG Study.” International Journal of Cardiology 168 (5): 5093–95. doi:10.1016/j.ijcard.2013.07.260.